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1. Introduction
The Barcelona Clinic Liver Cancer (BCLC) staging system
classiﬁes patients with hepatocellular carcinoma (HCC)
into ﬁve groups based on: performance status, liver
function and tumour burden. 1,2 Endorsed by the
European Association for the Study of the Liver (EASL)
and the American Association for the Study of Liver
Diseases (AASLD), the BCLC staging system is a validated
tool, 3−5 which is widely used in clinical practice in
Western countries for the prognostic stratiﬁcation of
patients and the assignment of treatment by disease
stage (Fig. 1). 1,2 Even so, treatment strategies which rely
solely on the BCLC staging classiﬁcation have a number
of limitations, including the inability to distinguish
subgroups of patients with BCLC stage A who are
not suitable for resection, ablation or transplant, and
patients with BCLC stage B who are poor candidates
for TACE. 6 Moreover, the treatment guidance based on
the BCLC staging suggests no alternatives for patients
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failing on the recommended treatments such as TACE or
sorafenib.
2. Limitations of BCLC staging
Investigators from the Memorial Sloan-Kettering Cancer
Center, New York found that the BCLC staging system
ranked sixth amongst the staging systems in accurately
predicting outcome among patients with advanced HCC,
with Cancer of the Liver Italian Program (CLIP) and the
Chinese University Prognostic Index (CUPI) considered
the best. 7 Another analysis found that the BCLC system
was a poor predictor of outcome among patients who
received transarterial chemoembolisation (TACE) as their
primary therapy. Subgroups of patients beneﬁtting from
TACE were identiﬁed within the groups of patients with
intermediate (BCLC stage B) and also with advanced
(BCLC stage C) HCC. Important factors correlating with
the outcome from TACE were found to be the tumour
features as well as laboratory parameters including
bilirubin, albumin, alpha-fetoprotein (AFP), and platelet
count (unpublished data).
The Pamplona group have shown that patients with
BCLC stage B HCC are potentially eligible for a range of
1359-6349 © 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.
28 ejc supplements 10, no. 3 (2012) 27–29
HCC
Stage 0
Very Early Stage
single <2 cm or
carcinoma in situ
Resection
portal pressure;
bilirubin
single
Llovet JM, DiBisceglie AM, Bruix J et al, Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698–711.
Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of Hepatocellular Carcinoma: An Update. Hepatology 2010 July;
ePub. http://www.aasld.org/practiceguidelines 2010.
increased associated diseases
normal no yes
3 nodules <3 cm
portal vein invasion,
N1 M1 or PS 1–2
single nodule or
3 nodules <3 cm
PS 0
Stage A
Early Stage
Stage B
Intermediate Stage
Stage C
Advanced Stage
Stage D
End Stage
PS 0–2
Child A–B
PS 0
Child A
PS >2
Child C
Curative treatments – 5-year survival 40–70%
30% of patients
AblationLiver Transplant TACE
RCTs – median survival 11–20 months
50% of patients at presentation
survival <3 months
20% of patients
symptomaticsorafenib
multinodular; PS 0
PS >2 or Child C
(unless within
transplant criteria)
Fig. 1 – BCLC Staging classiﬁcation and treatment schedule. Reproduced with permission from Llovet JM, DiBisceglie AM,
Bruix J, et al. 1 Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698–711.
Fig. 2 – Clinical outcomes of HCC patients treated with 90Y resin microspheres.
treatments, and those who were able to undergo radical
therapies survived signiﬁcantly longer than those treated
by locoregional therapies or best supportive care. 6 This
is due, for the most part, to speciﬁc contraindications
or technical limitations that can inﬂuence treatment
decision beyond the BCLC criteria. It has been known
for over a decade, for example, that subgroups of
patients with a tumour size 5 cm and portal vein
obstruction are poor candidates for TACE 8 and many
other factors including, for example, the treatment
approach (lobar embolisation vs. super selective) are
important in determining the outcome with TACE. 9,10
3. The place of SIRT
The European Network on Radioembolisation with
Yttrium-90 resin microspheres (ENRY) group, in an
analysis of patients with either early (BCLC stage A),
intermediate (BCLC stage B) or advanced (BCLC stage C)
HCC, concluded that survival with selective internal
radiation therapy (SIRT or radioembolisation) was similar
to TACE (~23 months) among patients who were
potentially good candidates for TACE (i.e. patients
with unilobar or less than 5 nodules) and where a
superselective approach with TACE would be possible
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Table 1 – Clinical experience with SIRT using yttrium-90 resin microspheres in HCCA
Typical candidates for TACE
BCLC stage A (unresectable; non-ablatable)
BCLC stage B with unresectable unilobar disease or limited number of nodules (1−5)
Patients not amenable to TACE
BCLC stage B with bilobar and/or multinodulular (>5) disease
After TACE/TAE failure
Candidates for sorafenib
Patients with liver-dominant BCLC stage C and appropriate liver function
(Fig. 2). 11 Beyond this group, SIRT was also effective in
a subgroup of patients who would be considered poor
candidates for TACE, and survival among these patients
was similar those who had failed priorTACE (~15months)
(Fig. 2). 11
During the multidisciplinary review of patients at
Munich, SIRT is routinely considered as an alternative
to TACE especially for those with intermediate (BCLC
stage B) HCC with large tumour burden which has spread
to both lobes. In patients with advanced (BCLC stage C)
HCC, SIRT appears to be an effective therapy in patients
with progression on sorafenib and patients with liver-
dominant disease who have a preserved liver function.
4. Conclusions
In conclusion, the evidence supporting the use of SIRT
in HCC is mounting, especially for those patients not
well served by the existing BCLC treatment algorithm
(Table 1). Further randomised controlled trials are needed
to further deﬁne the efﬁcacy and safety of this emerging
treatment.
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